Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CTEC.L and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CTEC.L and 80,000+ other tickers.
See exactly how CTEC.L's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CTEC.L and 80,000+ other tickers.
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals…
Convatec (LSE: CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Compa
FTSE down 4 points at 9,699 UK GDP slips 0.1% in October Silver touches a new high US futures point to mixed start 1.42pm: Trump moves to loosen AI red...
FTSE adds 33 points to 9,736 UK GDP slips 0.1% in October Frankfurt's DAX and Paris CAC 40 gain US futures point to mixed start 9.30: Positive mood in...